Januvia & Byetta Lawsuit
If you are considering filing a Januvia and Byetta lawsuit because you have suffered pancreatic injuries from these popular diabetes drugs, you need a law firm that will make a strong stand against the powerful pharmaceutical companies that produced them.
At Edelman, Krasin & Jaye, we believe that our client’s success is our success. With over 25 years of experience and $500 million in jury verdicts and settlements, our product liability attorneys have demonstrated time and again that they have the will, experience, and knowledge to procure substantial settlements for our clients in dangerous drug and other product liability lawsuits.
Several recent studies have called into question the safety and effectiveness of Januvia and Byetta relative to older (and less expensive) diabetes medications. In particular, they have raised serious concerns about acute pancreatitis, pancreatic cancer, and thyroid cancer risks. Numerous pancreatic cancer lawsuits have already been filed by people just like you who have suffered medical side effects and require compensation for the expenses and losses that they have incurred.
If you are considering a lawsuit yourself, you can talk to one of our attorneys during a no-cost consultation to get the answers you need. One of our Januvia and Byetta attorneys can walk you through the process of filing a lawsuit and evaluate whether you may have a viable case. Remember that you will pay no legal fees unless we win a settlement or jury verdict in your favor.
The facts about Januvia & Byetta
Januvia and Byetta are drugs that treat Type 2 diabetes, a condition in which the body does not produce sufficient insulin, allowing sugar to remain in the blood rather than being transferred to the cells. The condition, if untreated, can result in serious complications for a patient.
Known as incretin mimetics, the drugs work by controlling an enzyme (DPP-IV) that interferes with the release of insulin. Byetta (exenetide), which was approved by the FDA in 2005, supplies proteins that stimulate insulin and are not affected by DPP-IV. Januvia (sitagliptin), approved in 2006, simply stops DPP-IV from working at all so that insulin is released and the body can process sugar correctly. Byetta is injected, while Januvia is taken orally.
Byetta is manufactured by Amylin, Eli Lilly and Bristol-Myers; Januvia is manufactured by Merck. Both drugs have been incredibly lucrative for the pharmaceutical companies that produce them and the companies claim that their own studies have shown the drugs to be safe.
Januvia and Byetta: side effects, studies and the FDA
Despite the companies’ claims about the drugs’ safety, Januvia and Byetta have been linked to many side effects, the most serious of which include:
- Pancreatic cancer
- Thyroid cancer
Three major studies last year offered strong evidence of these risks:
- February, 2013: Johns Hopkins University School of Medicine researchers publish a study in the JAMA – Internal Medicine comparing 1269 patients taking GLP-1 medicines (including Januvia and Byetta) with 1269 patients taking other kinds of medications: 87 from the first group were hospitalized with acute pancreatitis vs. only 58 from the second group.
- March, 2013: Peter Butler, head of endocrinology at UCLA, publishes a study of pancreases taken from 34 deceased organ donors who had died of non-pancreas related illnesses. He found that in 8 of the donors taking Januvia or Byetta, there were far more precancerous lesions and one tumor, as well as abnormal cell growth. (Butler and colleagues had already found in 2008 that sitagliptin consumption led to enlarged pancreases and pre-cancerous cell growth in rats.)
- April, 2013: The Institute for Safe Medication Practices, a non-profit group, publishes an analysis of data from the FDA showing that increasing numbers of patients taking medications that included Januvia and Byetta suffered from pancreatitis, pancreatic cancer, and thyroid cancer.
Following the publication of the JAMA study and reports of the then unpublished study by Butler and colleagues, the FDA issued a safety communication announcing that they would be evaluating the safety of incretin mimetic drugs, including Byetta and Januvia.
Filing a Byetta or Januvia lawsuit
If you believe that you have been harmed by Januvia or Byetta, contact Edelman, Krasin & Jaye to discuss your eligibility to file a personal injury lawsuit. Pending lawsuits against the companies in question claim that they created an unreasonably dangerous drug and failed to warn about risks that the drugs posed.
A Januvia or Byetta lawsuit may provide you with compensation for medical bills, expenses related to ongoing treatment of diabetes, lost wages, and pain and suffering. Additionally, family members of a patient who has died as a result of taking one of these drugs may be eligible to file a wrongful death action.
Pancreatic cancer litigation
Pancreatic cancer lawsuits have been brought against the manufacturers of both Januvia and Byetta. Because the legal circumstances and side effects of the drugs are so similar, lawsuits concerning both drugs (as well as two others, Janumet and Victoza) have been centralized as of August 2013 as part of a multidistrict litigation (or MDL) at the federal court of the Southern District of California, in San Diego.
An MDL involves the consolidation of several lawsuits under one judge for the purpose of pre-trial discovery for maximum efficiency. However, each personal injury lawsuit will be heard on its own, with its own individualized outcome. Well over 200 cases are now involved, with the possibility that more will be added to MDL No. 2452, and that thyroid cancer suits could soon be included.
Edelman, Krasin, and Jaye can help you
If you have been diagnosed with pancreatitis or cancer of the pancreas after taking Januvia or Byetta, contact Edelman, Krasin & Jaye to discuss your eligibility for pursuing damages in a court of law. Call us toll free at 1-800-469-7429 to speak to one of our Januvia and Byetta attorneys.
- Consumer Reports, New concerns over Byetta and Januvia underscore the value of older and cheaper diabetes drugs http://news.consumerreports.org/health/2013/03/new-concerns-over-byetta-and-januvia-underscore-the-value-of-older-and-cheaper-diabetes-drugs.html
- JAMA Internal Medicine, Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus, A Population-Based Matched Case-Control Study http://archinte.jamanetwork.com/article.aspx?articleid=1656537#RESULTS
- Diabetes, Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with increased Exocrine Pancreas Dysplasia and the potential for Glucagon-producing Neuroendocrine Tumors http://diabetes.diabetesjournals.org/content/early/2013/03/17/db12-1686.abstract
- Medical News Today, FDA Investigates Safety Of Type 2 Diabetes Drugs Januvia And Byetta http://www.medicalnewstoday.com/articles/257705.php
- Medical News Today, Some Diabetes Drugs Linked To Pancreatitis Risk http://www.medicalnewstoday.com/articles/257103.php
- FDA, FDA Approves New Treatment for Diabetes, First in a New Class of Diabetes Drugs http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108770.htm